Innate Pharma : Visibilité financière jusqu’en 2024
>Chiffres T1 - Innate Pharma publie ce matin son chiffre d’affaires et sa trésorerie du premier trimestre 2022.Les revenus ressortent à 2.6 M€ et proviennent essentiellement de l’étalage des paiements d’étapes reçus dans le cadre de son partenariat avec Astrazeneca. La trésorerie à fin mars 2022 s’établit à 131.7 M€ contre 159.7 M€ fin 2021. Celle-ci ne comprend le paiement milestone de 50 M$ reçu d’Astrazeneca en avril dernier à la suite du dosage du premier patient ...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.